Bowel obstruction medical therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
Overview
Overview
The mainstay treatment of bowel obstruction is surgical and non-operative management. The role of medical therapy is supportive and is limited by palliative pain management in cancer patients, fluid and electrolyte replenishment, decreasing abdominal distension, peritumoral edema, intraluminal secretions, peristaltic movements, and control of nausea and vomiting.
Medical Therapy
Medical Therapy
The mainstay treatment of bowel obstruction is surgical and non-operative management. The role of medical therapy is supportive and is limited by control of vomiting and nausea, fluid and electrolyte replenishment, and palliative pain management in cancer patients. Glucocorticoids, octreotide and anticholinergic agents can be used to decrease abdominal distension, peritumoral edema, intraluminal secretions, and peristaltic movements. Antibiotics also play a role in treating infections but are not routinely recommended.[1][2][3][4][5][6][7][8][9]
- 1 Antiemetics
- 1.1 Antiemetics in cancer patients
- 1.1.1 Adult
- Note (1): Used in conjunction with nasogastric decompression
- Preferred regimen (1): Haloperidol 0.5 -2 mg and up to 20 mg PO q6h IV or SC
- Preferred regimen (2): Dexamethasone 4 mg q12h IV or SC
- Preferred regimen (3): Octreotide 0.1 mg and up to 0.3 mg q8h IV or SC
- Alternative regimen (1): Hyoscine (scopolamine) hydrobromide 0.2 – 0.4 mg q6 – 8h SC or transdermal
- Alternative regimen (2): Chlorpromazine, prochlorperazine, or cyclizine 0.2 – 0.4 mg q6 – 8h SC or IV or rectally
- Alternative regimen (3): Octreotide 300 Β΅g once daily
- Alternative regimen (4): Metoclopramide 30 – 60 mg q24h SC
- 1.1.2 Antiemetics in non-cancer patients
- Preferred regimen (1): Promethazine 12.5-25 mg q4 – 6h PRN or PO, alternatively 12.5-25 mg q4 – 6h IV or IM
- Preferred regimen (2): Ondansetron 4 – 8 mg q8-12hr PO or IV
- 1.1.3 Pediatric
- 1.1.3.1 Children 1 month – 12 years of age
- Preferred regimen (1): Ondansetron <40 kg, 0.1 mg/kg IV
- Preferred regimen (2): Ondansetron >40 kg, 4 mg IV
- 1.1.3.1 Children < 2 years of age
- Preferred regimen (1): Promethazine – contraindicated
- 1.1.3.2 Children > 2 years of age
- Preferred regimen (1): Promethazine 0.25-1 mg/kg PO/PR q4-6hr; not > 25 mg
- 1.1.3.2 Children > 12 years of age
- Preferred regimen (1): Ondansetron 4 mg IV/IM or 16 mg PO 1 hr
- 1.1.3.1 Children 1 month – 12 years of age
- 1.1.1 Adult
- 1.1 Antiemetics in cancer patients
- 2 Fluid and electrolyte replacement
- 2.1 Fluid replacement
- 2.1.1 Adult
- Parenteral regimen
- Preferred regimen (1): Isotonic saline or lactated Ringer’s solution 1 – 2 L IV initially, in addition to administration of fluid equal to the urine output plus insensible fluid losses (approx. 30 – 50 ml)
- Parenteral regimen
- 2.2 Electrolyte replacement
- Hyponatremia
- Hypokalemia
- Preferred regimen (1): Potassium 40 mEq/L or 3.0 g per L not > 80 mEq/L
- Note (1): Replacement is only necessary if deficit continues for >48h, or in excess of 2L in 24h
- Hypochloremia
- Preferred regimen (1): Chloride 40 mEq/L not> 80 mEq/L
- 2.1.1 Adult
- 2.1 Fluid replacement
- 3 Pain management in cancer/non-cancer patients
- 3.1 Non-opioids
- 3.1.1 Adult
- Preferred regimen (1): Acetaminophen 325β1000 mg PO q4β6h PRN
- Alternative regimen (2): Aspirin 325β650 mg PO q4h PRN
- Alternative regimen (3): Diclofenac 50 mg PO BID-TID
- Alternative regimen (3): Etodolac 200β400 mg PO q6β8h
- Alternative regimen (4): Ibuprofen 400β600 mg POq 4β6h PRN
- Alternative regimen (5): Indomethacin 25β50 mg PO TID
- Alternative regimen (6): Ketoprofen 25β50 mg PO q6hβq8h
- Alternative regimen (7): Ketorolac 10 mg PO q4β6h PRN or 30 mg IV/IM q6h
- Alternative regimen (8): Meclofenamate 50β100 mg PO q4β6h PRN
- Alternative regimen (9): Mefenamic acid 250 mg PO q4β6 PRN
- Alternative regimen (10): Meloxicam 7.5β15 mg PO once daily
- Alternative regimen (11): Nabumetone 100β2000 mg once daily
- Alternative regimen (12): Naproxen 250β500 mg PO BID
- Alternative regimen (13): Oxaprozin 1200 mg PO once daily
- Alternative regimen (14): Piroxicam 20 mg PO once daily
- Alternative regimen (15): Sulindac 150β200 mg PO BID
- Alternative regimen (16): Tolmetin 200β600 mg PO BID-TID
- Alternative regimen (17): Tramadol 50β100 mg PO q4β6h PRN; 100 β 300 mg QD for SR
- Alternative regimen (18): Celecoxib 200 mg PO BID
- 3.1.1 Adult
- 3.2 Opioids
- 3.2.1 Adult
- Preferred regimen (1): Morphine sulfate 10β30 mg q3β4h PO
- Alternative regimen (1.2): Rectal suppository; 10β20 mg q4h
- Alternative regimen (1.3): PRN; 2.5β10 mg q2β6h
- Alternative regimen (1.4): Epidural; 3β5 mg once, then 0.1β0.7 mg/hr
- Alternative regimen (1.5): Intrathecal; start 100:1 IT-to-IV, then titrate to pain
- Alternative regimen (1.6): Controlled release tab 15β30 mg q8β12h
- Alternative regimen (1.7): Sustained release tab 15β30 mg q8β12h
- Alternative regimen (1.8): Extended release capsule 20 mg q24h, may increase by 20 mg increments every other day
- Alternative regimen (1.9): Extended release capsule 30 mg q24h, may increase by 30 mg increments q4days (max 1600 mg/d)
- Alternative regimen (2): Codeine 15β60 mg q4β6h (max 60 mg/d)
- Alternative regimen (3): Dilaudid 2β8 mg q3-4h for PO and PR
- Alternative regimen (4): Roxycodone 5β30 mg q4h
- Alternative regimen (5): Oxycontin 10β160 mg q12h
- Alternative regimen (6): Opana 5β10 mg q4β6h
- Alternative regimen (7): Opana extended release 5β40 mg q12h
- Alternative regimen (8): Propoxyphene HCl 65 mg q4h (max 390 mg/24h)
- Alternative regimen (9): Methadone 2.5β10 mg q3-6h
- Note (1): Has very long half-life (8β60 hours)
- Alternative regimen (10): Meperidine 50β150 mg q3β4h
- Note (2): Decrease dose if given IV, administer slow or via PCA. Not recommended for chronic use.
- Alternative regimen (11): Fentanyl 25β100 mcg q1β2h or 0.5β1.5 mcg/kg/hr IV infusion via PCA
- Alternative regimen (12): Actiq; start with 200 mcg for breakthrough pain episodes, then titrate to pain
- Alternative regimen (13): Duragesic 25 mcg/h q72hr, may increase q3β6days
- 3.2.1 Adult
- 3.1 Non-opioids
- 4 Anti-edema
- 4.1 Glucocorticoids
- 4.1.1 Adult
- Preferred regimen (1): Dexamethasone 6 – 16 mg IV or SC daily for 3 – 5 days, not > 7 days
- Alternative regimen (1): Prednisolone 15 – 50 mg IV or SC daily for 3 – 5 days, not > 7 days
- 4.1.1 Adult
- 4.1 Glucocorticoids
- 5 Anti-secretion, anti-peristaltic, and anti-emetic
- 5.1 Anticholinergics
- Preferred regimen (1): Hyoscine 10 – 20 mg IM or IV daily
- Alternative regimen (2): Glycopyrrolate 0.004 mg/kg IM or IV
- 5.1 Anticholinergics
- 6 Infection management
- 6.1 Antibiotics
- 6.1.1 Adult
- Preferred regimen (1): Cefazolin 2 g IV q12hr severe infection, 3 g IV q12hr life-threatening infection
- Alternative regimen (2): Cefoxitin 1 g IV q4hr or 2 g IV q6-8hr severe infection, 6-8 g/day maximum in life threatening
- Alternative regimen (3): Cefotetan 2 g IV q12hr severe infection, 3 g IV q12hr life-threatening infection
- Alternative regimen (4): Cefuroxime 1.5 g IV/IM q8hr severe infection; q6hr in life-threatening circumstances
- Alternative regimen (5): Meropenem 1 g IV q8hr severe infection; not > 2 g IV q8hr
- 6.1.2 Pediatric
- 6.1.2.1 Neonate < 7 days old
- Preferred regimen (1): Cefazolin 40 mg/kg q12h IV or IM daily divided
- Alternative regimen (2): Cefuroxime 100 mg/kg q12h IV or IM daily divided
- Alternative regimen (3): Meropenem 20 mg/kg q8h IV; not > 1 g q8h
- 6.1.2.2 Infants > 7 days old
- Preferred regimen (1): Cefazolin 25-100 mg/kg q6-8h IV or IM daily divided; not > 6 g daily
- Alternative regimen (2): Cefoxitin 80-160 mg/kg q4-6h IV daily divided
- Alternative regimen (3): Cefotetan 40-80 mg/kg q12h IV or IM daily divided
- Alternative regimen (4): Cefuroxime 150 mg/kg q8h IV or IM daily divided
- Alternative regimen (5): Meropenem 20 mg/kg q8h IV; not > 1 g q8h
- 6.1.2.1 Neonate < 7 days old
- 6.1.1 Adult
- 6.1 Antibiotics
- 7 Prokinetics
- Preferred regimen (1): Metoclopramide 10 mg q4h SC or 60 – 200 mg SC daily continuous injection
- Note (1): Contraindicated in complete bowel obstruction
- Alternative regimen (2): Domperidone 10 mg PO QID
- Preferred regimen (1): Metoclopramide 10 mg q4h SC or 60 – 200 mg SC daily continuous injection
References
References
- β Sagar PM, MacFie J, Sedman P, May J, Mancey-Jones B, Johnstone D (1995). “Intestinal obstruction promotes gut translocation of bacteria”. Dis. Colon Rectum. 38 (6): 640β4. PMIDΒ 7774478.
- β LE QUESNE LP (1955). “Fluid balance in intestinal obstruction”. Postgrad Med J. 31 (355): 227β33. PMCΒ 2500705. PMIDΒ 14371195.
- β Khoo D, Hall E, Motson R, Riley J, Denman K, Waxman J (1994). “Palliation of malignant intestinal obstruction using octreotide”. Eur. J. Cancer. 30A (1): 28β30. PMIDΒ 7511400.
- β Spears H, Petrelli NJ, Herrera L, Mittelman A (1988). “Treatment of bowel obstruction after operation for colorectal carcinoma”. Am. J. Surg. 155 (3): 383β6. PMIDΒ 3344898.
- β Ripamonti CI, Easson AM, Gerdes H (2008). “Management of malignant bowel obstruction”. Eur. J. Cancer. 44 (8): 1105β15. doi:10.1016/j.ejca.2008.02.028. PMIDΒ 18359221.
- β Blair SL, Chu DZ, Schwarz RE (2001). “Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer”. Ann. Surg. Oncol. 8 (8): 632β7. PMIDΒ 11569777.
- β Higashi H, Shida H, Ban K, Yamagata S, Masuda K, Imanari T, Yamamoto T (2003). “Factors affecting successful palliative surgery for malignant bowel obstruction due to peritoneal dissemination from colorectal cancer”. Jpn. J. Clin. Oncol. 33 (7): 357β9. PMIDΒ 12949063.
- β Frank C (1997). “Medical management of intestinal obstruction in terminal care”. Can Fam Physician. 43: 259β65. PMCΒ 2255220. PMIDΒ 9040913.
- β Mercadante S, Ferrera P, Villari P, Marrazzo A (2004). “Aggressive pharmacological treatment for reversing malignant bowel obstruction”. J Pain Symptom Manage. 28 (4): 412β6. doi:10.1016/j.jpainsymman.2004.01.007. PMIDΒ 15471659.
ββ
Looking for the patient version?
Β© 2026 MyEClinic β IFTM Institut fΓΌr Telematik in der Medizin GmbH
